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During Wave IV, Add Health collected biological specimens from a large, nationally 
representative sample of young adults.  Given the size of the Wave IV sample, its geographic 
distribution, and in-home setting of the respondent interviews, biological specimen collection 
involved practical, relatively non-invasive, cost-efficient and innovative methods.  These 
methods included collection of capillary whole blood via finger prick by trained and certified 
field interviewers, its in situ desiccation, then shipment, assay and archival of dried blood spots.  
The collection of capillary whole blood followed the collection of cardiovascular and 
anthropometric measures (Entzel et al., 2009) and saliva (in preparation).  It preceded the 
collection of data on respondent use of prescription and select over-the-counter medications 
(Tabor et al., 2010).  Further details on the design of Add Health Waves I-IV, are available 
elsewhere (Harris, 2011). 
 
Included in the Add Health Wave IV data are two measures of glucose homeostasis based on 
assay of the dried blood spots:    
 
 Glucose (mg/dl) and 
 Hemoglobin A1c (HbA1c, %) 
 
To facilitate analysis and interpretation of HbA1c, the restricted-use Add Health Wave IV data 
also include a trichotomous flag distinguishing the original (0) from two types (1,2) of inter-
converted assay results (see Section 4.2.3.3): 
 
 Convert (0,1,2) 
 
Moreover, the restricted-use Add Health Wave IV data include six constructed measures: 
 
 Fasting duration (h) 
 Classification of fasting glucose (ADA, 2011) 
 Classification of non-fasting glucose (ADA, 2011) 
 Classification of HbA1c (ADA, 2011) 
 Anti-diabetic medication use 
 Joint classification of glucose, HbA1c, self-reported history of diabetes, and anti-diabetic 
medication use 
 
This document summarizes the rationale, equipment, protocol, assay, internal quality control, 
data cleaning, external quality control, and classification procedures for each measure listed 




assay of the dried blood spots and genotyping of DNA extracted from salivary buccal cells will 
be provided in separate reports.   
2. General Overview of Data Collection  
 
A Blaise computer-assisted interview (CAI) program guided trained and certified field 
interviewers (FIs) through the blood spot collection process.  Help screens with step-by-step 
measurement instructions were accessible within the program.  Each FI also carried a Job Aids 
Booklet that served as a quick reference guide to study protocols. 
 
Respondents were free to decline any or all measurements and specimen collections while 
participating in other components of the interview.  In the Wave IV data set, any measures that 
are missing due to unique circumstances at correctional facilities are coded as legitimate skips.   
 
Some measurement protocols were revised in the period between the Wave IV Pretest 
(conducted in 2007) and the Main Study (conducted in 2008).  Where the Pretest and Main Study 
data collection protocols differed significantly, this report documents the key differences 
between them.  Pretest cases in the Wave IV data set are flagged for identification.   
 
3. Capillary Whole Blood Collection  
 
3.1 Rationale  
 
Capillary whole blood was collected to provide Add Health with the biological specimens 
necessary to assay and interpret a pre-specified panel of metabolic, hematologic, inflammatory, 
and immune biomarkers, including the measures of glucose homeostasis described herein.  It 
also was collected to establish a dried capillary whole blood spot archive capable of supporting 
future assays and ancillary studies.  
 


















Sterile lancets, rubber strap, alcohol prep pads, gauze, Band-Aid type adhesive dressings, gloves, 
biohazard container, Chux-type absorbent underpad, and a seven-spot capillary whole blood 
collection card (Whatman 903® Protein Saver, Whatman Inc., Piscataway, NJ) to which a 




3.3.1 Main Study 
 
During the preceding anthropometric data collection procedure, all female respondents were 
asked specifically whether they had a prior mastectomy and, if so, on which side.  If there were 
contraindications to using the right hand for capillary whole blood collection, the left hand was 
used.  If there were contraindications on both hands, capillary whole blood was not collected.       
 
FIs collected capillary whole blood from the respondent’s middle or ring finger, unless one of the 
following contraindications was present:   
 
 open sores, wounds, gauze dressings or rashes; 
 casts, splints or shunts; 
 intravenous (IV) catheters or other attached medical devices; 
 swelling, withering or paralysis; or 
 finger on same side as prior mastectomy.   
 
FIs prepared the work surface for capillary whole blood collection and donned gloves. The help 
screen on the computer laptop directed FIs to refer to the Job Aids Booklet for the Fainting 
Protocol.  FIs selected a finger for the procedure, cleaned it with the alcohol prep pad, and let it 
fully dry.  While the finger was drying, FIs asked respondents to hang the selected finger below 
their waist while applying the rubber strap to the midpoint of the upper, ipsilateral arm.  After 
placing the rubber strap, respondents started a timer on the laptop computer designed to sound an 
audible cue after three minutes to prompt removal of the rubber strap.  FIs placed the clean finger 
against the work surface and firmly placed a sterile lancet against it to prick the fingertip, slightly 
lateral of center. FIs firmly wiped away the first drop of capillary whole blood with gauze, 
applying pressure to the base of (but not milking) the finger to facilitate flow. FIs were trained to 
allow a large droplet to accumulate before dropping it onto the first circle of the seven-spot 
capillary whole blood collection card and to do the same for the remaining six circles from left to 




Exhibit 2. Collecting the capillary whole blood. 
 
When seven capillary whole blood spots were successfully collected (or blood droplet formation 
ceased), FIs wiped off remaining blood with gauze, instructed respondents to firmly apply the 
gauze to the finger for at least two minutes, and then applied a band aid to it.  FIs collecting 
fewer than five spots less than 80% full from a single prick requested respondents’ permission to 
repeat the capillary whole blood collection procedure on a second finger from the contralateral 
hand.  FIs asked respondents to discard used capillary whole blood collection equipment in their 
own trash receptacle (except for lancets which were discarded in the biohazard container).  FIs 
discarded them in the biohazard container when interviews were conducted in public locations. 
 
FIs bar code labeled each capillary whole blood spot collection card with the corresponding 
respondent biospecimen ID and then air dried it for three hours.  Thereafter, FIs packaged each 
card with a desiccant pack and shipped it in a FedEx Priority Overnight envelope to the 
University of Washington Department of Laboratory Medicine (UW Lab Med, Mark H. Wener, 
M.D., Director, Seattle, WA) for assay. 
 
UW Lab Med received the FedEx Priority Overnight envelopes containing a single dried blood 
spot collection card and desiccant pack.  They scanned the FedEx tracking number and bar code-
labeled card into a database in the order of receipt. They also keyed the receipt date, number of 
dried blood spots per card (0-7), number of adequate blood spots per card defined by blood 
filling ≥ 80% of the target area (0-7), comments on dried blood spot quality, and condition of the 
desiccant pack alongside the biospecimen ID.  They grouped the cards (≤ 25 per group), sealed 
the groups in Ziploc bags with desiccant packs, and stored them at -70°C until processing.  
Immediately before processing, they warmed cards to room temperature (23°C) and re-scanned 
the bar code-labeled card into the database.  The cards were punched for all assays except HbA1c, 
returned to the freezers, then shipped frozen to the Carolina Population Center (CPC, University 
of North Carolina, Chapel Hill, NC) for permanent archival.  At the CPC, Spot #1 on each card 
was removed, re-bundled (≤ 25 per group), sealed in plastic bags with desiccant, and shipped 
frozen by next day air to FlexSite Diagnostics, Inc. (Robert A. Ray, Ph.D., Director, Palm City, 
FL) for HbA1c assay. 
 




During the Pretest, respondents chose the middle or ring finger and FIs were directed not to use 
the thumb, index finger or fifth digit/little finger for capillary whole blood collection.  FIs also 
collected up to ten capillary whole blood spots:  three on a BIOSAFE Blood Collection Card for 
HbA1c and Cholesterol Panel (BIOSAFE Laboratories, Inc., Chicago, IL) and seven more on a 
Whatman 903® Protein Saver, (Whatman Inc.,  Piscataway, NJ).  The BIOSAFE card was made 
of Whatman 903® filter paper (Whatman International, Dassel, Germany) with a top layer of 
TELFA (Kendall Healthcare Products, Mansfield, MA) to minimize the effects of blood spot 
layering and inadvertent touching of cards with respondent fingertips (Tyrrell, 1999; Maggiore, 
2002; Bui et al., 2002a; Bui et al., 2002b; Grzeda et al., 2002).  A stabilizing borate buffered 
preservative was pre-applied by BIOSAFE to the area of the BIOSAFE card designated for 
HbA1c assay and dried.  As in the main study, the Whatman 903® Protein Saver card was 
shipped to UW Lab Med for assay. 
 




4.1.1 Rationale  
 
Glucose was assayed in dried capillary whole blood spots because of its central role in the 
identification of impaired fasting glucose / pre-diabetes, and diabetes mellitus, two well-known 
risk factors for cardiovascular disease morbidity and mortality.   
 
4.1.2 Assay and Internal Quality Control 
 
UW Lab Med constructed dried blood spot glucose assay calibrators from pooled human plasma 
spiked with a concentrated glucose solution (Sigma, St. Louis, MO) and serially diluted with 7% 
bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma) to the desired final 
glucose concentration.  Two dried blood spot quality control samples were constructed from a 
separate pool of human plasma, either undiluted (high glucose concentration quality control 
sample) or diluted with BSA/PBS (low glucose concentration quality control sample).  Each 
calibrator and quality control sample solution was mixed 1:2 with washed human erythrocytes 
(UW Lab Med), pipetted in 75µl aliquots onto #903 filter paper (Whatman Inc., Piscataway, NJ) 
and dried for 4 hr at room temperature.  The glucose concentration of each calibrator and quality 
control sample solution was determined by analysis on a Synchron LX 20 Pro Clinical System 
(Beckman Coulter, Miami, FL).  Dried blood spot calibrators and quality control samples were 
stored at -70°C in sealed Ziploc bags with desiccant until use. 
A single 3.2 mm (1/8 in) diameter punch was taken from each dried blood spot calibrator, quality 
control sample or respondent sample and placed into a deep-well microtiter plate well (Greiner 
Bio-One, Monroe, NC).  Plates were either immediately assayed or were firmly sealed and stored 
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at -70°C pending assay.  Plates to be assayed were warmed to room temperature and then 75 µl 
of elution solution (PBS; Sigma) was added column-by-column to each well using an eight-
channel electronic pipettor (Rainin, Oakland, CA).  Plates were sealed and vigorously shaken for 
1 hr on a Delfia Plateshake microplate shaker (PerkinElmer, Waltham, MA). A 190 µl aliquot of 
glucose reagent (Synermed, Westfield, IN) was added column-by-column to the elution solution 
in each well, the plate sealed and the resulting reaction mixture incubated at 37°C for 30 min. A 
190 µl aliquot of the reaction mixture was transferred column-by-column from each well to a 
flat-bottom, shallow-well microtiter plate (Greiner Bio-One, Monroe, NC).  The optical density 
of each well (in arbitrary units) was then read at 660 nm on a Synergy HT Microtiter Plate 
Reader (BioTek, Winooski, VT).  Plate-specific linear regression calibration curves, 
electronically constructed by plotting the concentrations of the calibrators against absorbance 
values, were used to convert the optical density of each respondent sample into a dried blood 
spot glucose concentration (BioTek Gen5).  Respondent samples with a glucose concentration 
greater than the highest calibrator were diluted and re-assayed.  The sensitivity of the glucose 
assay was 22 mg/dl, the within-assay coefficient of variation was 4.4% and the between-assay 
coefficient of variation was 4.8%.  Glucose concentrations (mg/dl) of 83 paired dried blood spot 
and serum samples determined using the protocol described above and the conventional 
Beckman Coulter UniCel DxC 800 Synchron Clinical System were strongly correlated (Pearson 
r = 0.97) and linearly associated in Deming regression (Cornbleet et al., 1979; Deal et al., 2011):  
serum glucose (mg/dl) = 1.193 * dried blood spot glucose (mg/dl) + 2.617. Correction for 
hematocrit did not increase the strength of association. 








HbA1c was assayed in dried capillary whole blood spots because it is an integrated measure of 
glucose homeostasis, reflecting average blood glucose over the preceding two to three months. 
The measure plays a critical role in the management of diabetes since it is correlated with micro- 
and macrovascular complications and is widely used as the standard biomarker for the adequacy 
of glycemic management (American Diabetes Association, 2011). 
 
4.2.2 Assay and Internal Quality Control - Flexsite 1 HbA1c Assay 
 
FlexSite Diagnostics placed a 6.35 mm (1/4 in) diameter punch from each dried blood spot 
respondent sample in a microtiter plate, eluted blood from the punches, released hemoglobin 
(Hb) from the blood via hemolysis, proteolytically degraded it with pepsin, and oxidized heme 
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groups using Roche Unimate reagents.  Hb and HbA1c were then measured in the hemolysate on 
the Roche COBAS INTEGRA® 700 Analyzer (Roche Diagnostics, Indianapolis, IN) (Roche 
Diagnostics, 2005).  Total Hb was measured using a cyanide-free colorimetric method based on 
the formation of a brownish-green chromophore, alkaline hematin D-575, in alkaline detergent 
solution (Zander et al., 1984).  The color intensity (proportional to the total Hb concentration in 
the respondent sample) was determined by monitoring the increase in absorbance at 552 nm.  
Total Hb was calculated using a fixed factor determined from the primary calibrator, 
chlorohemin (Wolf et al., 1984).  HbA1c was measured using monoclonal antibodies attached to 
latex particles.  The antibodies bound the β-N-terminal fragments of HbA1c.  Remaining free 
antibodies were agglutinated with a synthetic polymer carrying multiple copies of the β-N-
terminal structure of HbA1c.  The change in turbidity (inversely related to the amount of bound 
glycopeptide in the respondent sample) was measured turbidimetrically at 552 nm.  A synthetic 
polypeptide compromising the N-terminal structure of HbA1c was used for calibration (Little et 
al., 1992).  HbA1c (%) was calculated from the HbA1c:Hb ratio, as follows:  HbA1c (%) = 2.27 + 
87.6 × (HbA1c ÷ Hb) (Rohlfing et al., 2002; NGSP, 2011).  At a total Hb of 13.2 g/dl, the 
sensitivity of the conventional Roche HbA1c assay was 3%.  The within- and between-run 
coefficients of variation assay were 2.2%-2.4% (Roche Diagnostics, 2005).  HbA1c (%) of 80 
paired dried blood spot and whole blood samples determined using the protocol described above 
and the conventional HbA1c assay on the Tosoh SRL#5 (Tosoh Bioscience, Inc., South San 
Francisco, CA) were strongly associated (Pearson r = 0.99) and linearly related:  dried blood spot 
HbA1c (%) = 1.014 × whole blood HbA1c (%) – 0.296. 
 
4.2.3 Pretest Methodological Variations 
 
During the Pretest period, HbA1c was measured by BIOSAFE Laboratories, Inc. in 53 
respondents and by FlexSite Diagnostics, Inc. in 129 respondents using a slightly modified 
version of the Roche Unimate / COBAS INTEGRA HbA1c assay described above.  Descriptions 
of the assays and the inter-conversion of their results follows. 
 
4.2.3.1 Assay and Internal Quality Control - Flexsite 2 HbA1c Assay 
 
The Roche Unimate / COBAS INTEGRA HbA1c assay described above was changed to a Roche 
Tina-quant Gen 2 / COBAS INTEGRA HbA1c assay to reduce potential interference from 
hemoglobin variants such as HbS, found in sickle cell trait (NGSP, 2011). 
 
4.2.3.2 Assay and Internal Quality Control - BIOSAFE HbA1c Assay 
 
Two, 3.0 mm (1/8 in) diameter punches were collected from a homogeneous region of each dried 
blood spot respondent sample using a calibrated hole punch (McGill Inc., Marengo, IL).  The 
punches were transferred to a pre-labeled 15 x 100 mm borosilicate tube (Fisher Scientific, 
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Pittsburgh, PA).  To each tube, 630 µl of Roche Hemolyzing Reagent (Roche Diagnostics, 
Indianapolis, IN) were added.  The tubes were rotated at 1000 rpm for 60 min at 25
o
C.   
Following centrifugation at 2400 rpm (1300g) at 25
o
C for 10 min, the eluate was analyzed for 
HbA1c using the Roche P-Modular System (Roche Diagnostics, Indianapolis, IN) and Roche 
Hemoglobin A1c Reagents which employ an immunoturbidimetric method for HbA1c quantitation 
and a colorimetric method for Hb quantitation, as described above.  HbA1c (%) was calculated 
using the formula:  HbA1c (%) = 91.5 × (HbA1c ÷ Hb) + 2.15 (Roche Diagnostics, 2006).  The 
Roche HbA1c method was certified by the National Glycohemoglobin Standardization Program 
as being traceable to the HbA1c reference method (NGSP, 2011).  Analytical runs were quality 
controlled with commercially available assayed whole blood control materials (BioRad 
Laboratories, Hercules, CA), and laboratory-prepared dried blood quality control cards (Streck, 
Inc., Omaha, NE).  At HbA1c between 5.0% and 11.0%, the ranges of within- and between-run 
coefficients of variation for the BIOSAFE HbA1c assay were 1.4%-3.2%, and 3.5%-7.6%, 
respectively.  HbA1c (%) of 115 paired dried blood spot and whole blood samples determined 
using the protocol described above and a conventional HbA1c assay were strongly associated 
(Pearson r = 0.99) and linearly related:  dried blood spot HbA1c (%) = 0.850 × whole blood 
HbA1c (%) + 0.8079 (BIOSAFE, 2006). 
 
4.2.3.3 Inter-Conversion of FlexSite 1, FlexSite 2 and BIOSAFE HbA1c Assay Results 
 
Four Add Health Wave IV Main Study respondents were randomly selected from those (n = 
14,148) with FlexSite 1 HbA1c assay results within each of 24 strata defined by race / ethnicity 
(non-Hispanic white; non-Hispanic black; Hispanic; other), sex (male; female) and HbA1c tertile 
(low, medium, high).  Collectively, the stratified, random sample included 4 × 24 = 96 
respondents whose dried capillary whole blood spot collection cards were resubmitted for 
Flexsite 2 HbA1c assay by laboratory staff masked to respondent identity.  The association 
between the natural log transformed FlexSite 1 and FlexSite 2 HbA1c assay results was modeled 
using Deming regression (Cornbleet et al., 1979; Deal et al., 2011) , i.e. log(FlexSite 1) = α + β × 
log(FlexSite 2) (Pearson r = 0.63).  Estimates of α, β and their 95% confidence intervals (CIs) 
were 0.22 (-0.13, 0.58) and 0.85 (0.65 to 1.06).  α and β were used to convert FlexSite 2 to 
FlexSite 1 HbA1c assay results among (n = 129) Pretest respondents with missing FlexSite 1  
 
Exhibit 3.  Mean HbA1c (%), before & after inter-conversion of assay results 








assay results (Convert=1).  The association between the natural log transformed FlexSite 2 and 
BIOSAFE HbA1c assay results also was modeled using Deming regression (Cornbleet et al., 
1979; Deal et al. 2011) , i.e. log(FlexSite 2) = γ + δ × log(BIOSAFE) (Pearson r = 0.66).  
Estimates of γ, δ and their 95% CIs were -1.91 (-3.20, -0.61) and 2.22 (1.43, 3.02).  α, β, γ and δ 
were used to serially convert BIOSAFE to FlexSite 2 to FlexSite 1 HbA1c assay results among (n 
= 53) Pretest respondents with missing FlexSite results (Convert=2).  Inter-conversion of HbA1c 
attenuated among-assay differences (Exhibit 3). 
 
5. Data Cleaning and External Quality Control 
 
5.1 Data Cleaning 
Plate-specific, linear regression calibration formulae (Section 4.1.2) were used to verify 
laboratory conversion of optical density to glucose concentration (mg/dl).  Dried blood spot 
respondent samples with glucose (mg/dl) in the lowest half percentile of the distribution were re-
assayed.  Original and repeat assay values were averaged.  Seasonal variation was examined by 
plotting dried blood spot and quality control glucose (mg/dl) versus assay date (2007-2009) on a 
single calendar time scale (1-366 days).  A previously described pattern of seasonal variation 
(Gikas et al., 2009; Kershenbaum et al., 2011; Tseng et al., 2005) was observed (Exhibit 4).  
Glucose (mg/dl) was therefore modeled as a function of time, represented by four seasonal 
terms:  sine(2Πjt÷366) and cosine(2Πjt÷366), where harmonic j = (1, 2) and time t = (1, 2, 3, …, 
366).  This non-linear model was adjusted for age (yr), sex (male; female), and race/ethnicity 
(non-Hispanic white; non-Hispanic black; non-Hispanic Asian/Pacific Islander; Mexican; other 
Hispanic/Latino; other race/multiracial).  Goodness of fit as measured by the Akaike information 
criterion was greatest for this model when compared to a variety of non-linear and linear 
alternatives.  The age-, sex- and race/ethnicity-adjusted harmonic terms estimated in the former 
model were subtracted from the assayed values of glucose (mg/dl).  Subtraction had little effect 
on the overall distribution, mean, or variance of glucose, but attenuated the observed seasonal 
variation (Exhibit 4). 





5.2 External Quality Control 
 
Within a race / ethnicity- and sex-stratified random sample of (n = 100) Add Health respondents 
among whom capillary whole blood was collected twice, one-two weeks apart, reliabilities of 
random (fasting or non-fasting) glucose (mg/dl) and interconverted HbA1c (%) were estimated as 
intra-class correlation coefficients (95% CI):  0.40 (0.22, 0.59) and 0.97 (0.96-0.98), 
respectively.  The reliability of (fasting) glucose was 0.67 (0.35-1.00) within the fasting subset of 
these respondents (n = 23).  Among three dried blood spot quality control samples assayed by 
masked FlexSite staff twice weekly for ten weeks (n = 60), mean absolute and relative bias 
(standard deviation) of interconverted HbA1c were 0.2% (0.1%) and 3.8% (2.8%) when 
compared to HbA1c conventionally assayed in paired whole blood on the Tosoh G7 Automated 
HPLC-HbA1c Analyzer (Tosoh Bioscience, Inc., South San Francisco, CA) by Duke University 
Health System Laboratories (Durham, NC).  HbA1c (%) was strongly correlated with fasting 
glucose (mg/dl) (Pearson r = 0.68).  The HbA1c-based estimated average glucose (Nathan et al., 
2008) and mean plasma glucose (Rohlfing et al., 2002) were 8% and 16% higher than fasting 
glucose (mg/dl).  Measures of the HbA1c-fasting glucose correlation and HbA1c-based 
overestimation of fasting glucose were similar in the National Health and Nutrition Examination 
Survey (2007-2008):  Pearson r = 0.75, 7% and 12%, respectively.  These findings suggest that 
carefully standardized, in-home collection of whole blood spots can yield valid and reliable 
measures of glucose homeostasis (Whitsel et al., 2012). 
 
6. Constructed Measures 
 
6.1 Fasting Status 
Variable:  FASTTIME 
In Interview Section 4: General Health and Diet, field interviewers asked respondents the 
following question:  “At what time did you last eat or drink anything other than water, including 
sugar-containing candy or gum?”  The response to the question was recorded in hours and 
minutes and designated AM or PM.  On-screen instructions of “12 MIDNIGHT IS AM. 12 
NOON IS PM” were provided to the field interviewer for clarification.  To calculate fasting 
times, responses to the above question were subtracted from the laptop timestamp at the start of 
the interview.  Since laptop clocks were set to Eastern Time for field work processing, the CPC 
Spatial Analysis Unit corrected interview start times using geocoded respondent locations, the 
time zones in which they were located, and the U.S. Daylight Savings Time schedule.  In a final 
step, fasting times also were adjusted for interviews that stopped prematurely, but resumed later.  
Data on fasting times (range: 0-23.9 hr) were missing for 141 respondents, the result of recoding 
implausible values (> 24 hr), missing time zone data, breakoff interviews that resumed before 24 
hours elapsed such that the question was not repeated, unrealistic computer timestamps, and 




6.2 Classification of Fasting Glucose 
Variable:  C_FGLU 
The classification of glucose concentrations among Add Health respondents who were fasting (≥ 
8 hr) at the time of blood collection was constructed based on the 2011 clinical practice 
recommendations for the diagnosis and classification of diabetes (ADA, 2011).  Classes of 
fasting glucose are defined as follows: 
Fasting* Glucose (mg/dl) ADA Class 
100-125 Impaired Fasting Glucose (IFG) / Pre-Diabetes 
≥ 126 Diabetes 
*Fasting for ≥ 8 hr 
 
6.3 Classification of Non-Fasting Glucose 
Variable:  C_NFGLU 
The classification of glucose concentrations among Add Health respondents who were non-
fasting (< 8 hr) at the time of blood collection was constructed based on the 2011 clinical 
practice recommendations for the diagnosis and classification of diabetes (ADA, 2011).  Classes 
of non-fasting glucose are defined as follows: 
Non-Fasting* Glucose (mg/dl) ADA Class 
≥ 200 Diabetes 
*Fasting for < 8 hr 
 
6.4 Classification of HbA1c 
Variable:  C_HBA1C 
The classification of HbA1c among Add Health respondents was constructed without regard to 
fasting status at the time of blood collection based on the 2011 clinical practice recommendations 
for the diagnosis and classification of diabetes (ADA, 2011).  Classes of HbA1c are defined as 
follows: 
HbA1c (%) ADA Class 
5.7-6.4 Pre-Diabetes 





6.5 Anti-diabetic Medication Use 
Variable:  C_MED 
Respondents who report using medications in the past four weeks associated with one or more of 
the following therapeutic classification codes  
(99) Antidiabetic Agents,  
(213) Sulfonylureas, 
(214) Non-Sulfonylureas, 
(215) Insulin,  
(216) Alpha-Glucosidase Inhibitors,  
(271) Thiazolidinediones,  
(282) Meglitinides,  
(309) Miscellaneous Antidiabetic Agents,  
(314) Antidiabetic Combinations,  
(371)  Dipeptidyl Peptidase 4 Inhibitors, 
(372)   Amylin Analogs, 
(373)   Incretin Mimetics 
were assigned a value of 1 for C_MED, anti-diabetic medication use.  Those who did not report 
taking medications in these classifications were assigned a value of 0. (Tabor et al., 2010) 
 
6.6 Joint Classification of Glucose, HbA1c, Self-Reported History of Diabetes, and Anti-
Diabetic Medication Use 
Variable:  C_JOINT 
Add Health respondents also were classified as having diabetes if they had a fasting glucose ≥ 
126 mg/dl (C_FGLU = 3) or non-fasting glucose ≥ 200 mg/dl (C_NFGLU = 2) or HbA1c ≥ 6.5%  
(C_HBA1C = 3) or self-reported history of diabetes except during pregnancy (H4ID5D = 1) or 




American Diabetes Association (ADA).  Diagnosis and classification of diabetes mellitus.  
Diabetes Care 2011;34:S62-S69. 
 
BIOSAFE Laboratories, Inc.  Hemoglobin A1c detection system.  Technical bulletin.  Dried 
blood spot hemoglobin A1c assay. Performance characteristics 2006;  P/N 4002, Rev. 0306. 
 
Bui TL, Warner CN, Ildefonso J, Pirucki TL, Dewey LM, Maggiore JA. Development of a dried 





Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison 
analysis.  Clin Chem 1979;25(3):432-8. 
 
Deal AM, Pate VW, El Rouby S.  Paper CC-014.  A SAS® Macro for Deming regression, 2011.  
Available at http://analytics.ncsu.edu/sesug/2009/CC014.Deal.pdf. 
 
Entzel P, Whitsel EA, Richardson A, Tabor J, Hallquist S, Hussey J, Halpern CT, Harris KM. 
Add Health Wave IV documentation: Cardiovascular and anthropometric measures. UNC 




European Association for the Study of Diabetes (EASD).  2010 Consensus statement of the 
worldwide standardisation of the haemoglobin A1c measurement, 2010.  Available at 
http://www.easd.org/easdwebfiles/statements/HbA1c_Consensus_Statement.pdf. 
 
Grzeda BR, Bui TL, Warner CN, Pirucki TL, Dewey LM, Maggiore JA. Development of a dried 
blood collection, transport and testing system for triglycerides.  Clin. Chem 2002;48(S):A106. 
 
Harris KM. Design features of Add Health. UNC Chapel Hill: Carolina Population Center, 2011. 
Available at http://www.cpc.unc.edu/projects/addhealth/data/guides/design%20paper%20WI-
IV.pdf 
Kershenbaum A, Kershenbaum A, Tarabeia J, Stein N, Lavi I, Rennert G.  Unraveling 
seasonality in population averages: an examination of seasonal variation in glucose levels in 
diabetes patients using a large population-based data set.  Chronobiol Int 2011; 28(4):352-60. 
 
Gikas A, Sotiropoulos A, Pastromas V, Papazafiropoulou A, Apostolou O, Pappas S. Seasonal 
variation in fasting glucose and HbA1c in patients with type 2 diabetes.  Prim Care Diabetes 
2009;3(2):111-4. 
 
Tseng CL, Brimacombe M, Xie M, Rajan M, Wang H, Kolassa J, Crystal S, Chen TC, Pogach L, 
Safford M. Seasonal patterns in monthly hemoglobin A1c values.  Am J Epidemiol 2005; 
15;161(6):565-74. 
 
Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH Jr, Jacobson JM, 
Zellmer V, Goldstein DE. Interlaboratory standardization of measurements of glycohemoglobins.  




Maggiore JA.  BIOSAFE Safe At Home Cholesterol Profile Blood Collection and Transport 
System.  US Food and Drug Administration, 510(k) Over-the-Counter Approval, 4/3/02:  
K012221. 
 
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average 
Glucose Study Group.  Translating the A1C assay into estimated average glucose values.  
Diabetes Care 2008;31(8):1473-8. 
 
National Glycohemoglobin Standardization Program (NGSP).  2011.  Available at  
http://www.ngsp.org/. 
 
Roche Diagnostics. COBAS INTEGRA 400/700/800.  Hemoglobin A1c.  Whole blood 
application – standardized according to IFCC.  2005-10, V 7 EN. 
 
Roche Diagnostics.  HbA1c II Package Insert Version 10, 03-2006.   
 
Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the 
relationship between plasma glucose and HbA(1c):  analysis of glucose profiles and HbA(1c) in 
the Diabetes Control and Complications Trial.  Diabetes Care 2002;25(2):275-8. 
 
Tabor J, Whitsel EA. Add Health Wave IV documentation: Prescription Medication Use. UNC 
Chapel Hill: Carolina Population Center, 2010  Available at  
http://www.cpc.unc.edu/projects/addhealth/data/guides/medication_documentation.pdf. 
 
Tyrrell SP. BIOSAFE Safe At Home Test Kit for Monitoring Hemoglobin A1c.  US Food and 
Drug Administration, 510(k) Over-the-Counter Approval; 11/26/99:  K991850. 
 
Whitsel EA, Nguyen QC, Suchindran CM, Tabor JW, Cuthbertson CC, Wener MH, Potter AJ, 
Killeya-Jones L, Hussey JM, Halpern CT, Harris KM.  Dried capillary whole blood spot-based 
hemoglobin A1c, fasting glucose, and diabetes prevalence in a nationally representative 
population of young U.S. adults:  Add Health, Wave IV.  Am Heart Assoc CVD Epid Prev / Nutr 
Phys Act Metab Sci Sessions, 2012. 
 
Wolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of 
haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardisation of the method 
using pure chlorohaemin.  Clin Chim Acta 1984;136(1):95-104. 
 
Zander R, Lang W, Wolf HU.  Alkaline haematin D-575, a new tool for the determination of 
haemoglobin as an alternative to the cyanhaemiglobin method.  I.  Description of the method.  
Clin Chim Acta 1984;136(1):83-93. 
 
